Roche’s Actemra Delayed By REMS, FDA Study Requirements
This article was originally published in The Pink Sheet Daily
Executive Summary
Roche expects to submit a complete response to FDA for the first-in-class IL-6 inhibitor for rheumatoid arthritis in the third quarter next year.